Abstract
Colorectal cancer (CRC) is one of the most common cancers globally and is associated with a high mortality rate. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in normal intestinal tissue function, but has also been implicated in the development of CRC. MicroRNAs (miRNAs) have also recently emerged as important regulators of cancer development and progression. They act by targeting multiple signaling pathways including the TGF-β signaling pathway. There is growing evidence demonstrating that miRNAs target various components of the TGF-β signaling pathway, including TGF-β1, TGF-β2, regulatory SMADs (SMAD1, 2, 3, 5 and 9), co-mediator SMAD4, inhibitory SMADs (SMAD6 and 7) and the TGF-β receptors, and thereby alter the proliferation and migration of CRC cells. In this review, we summarize the data concerning the interaction between TGF-β signaling pathway and miRNAs with the aim to better understanding the CRC molecular mechanisms and hence better management of this disease.
Keywords: SLCO1B1, atorvastatin, safety, lipid-lowering effects, meta-analysis, colorectal cancer.
Current Pharmaceutical Design
Title:The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer
Volume: 24 Issue: 39
Author(s): Reyhaneh Moradi-Marjaneh, Majid Khazaei, Gordon A. Ferns and Seyed H. Aghaee-Bakhtiari*
Affiliation:
- Bioinformatics Research Group, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: SLCO1B1, atorvastatin, safety, lipid-lowering effects, meta-analysis, colorectal cancer.
Abstract: Colorectal cancer (CRC) is one of the most common cancers globally and is associated with a high mortality rate. The transforming growth factor beta (TGF-β) signaling pathway plays an important role in normal intestinal tissue function, but has also been implicated in the development of CRC. MicroRNAs (miRNAs) have also recently emerged as important regulators of cancer development and progression. They act by targeting multiple signaling pathways including the TGF-β signaling pathway. There is growing evidence demonstrating that miRNAs target various components of the TGF-β signaling pathway, including TGF-β1, TGF-β2, regulatory SMADs (SMAD1, 2, 3, 5 and 9), co-mediator SMAD4, inhibitory SMADs (SMAD6 and 7) and the TGF-β receptors, and thereby alter the proliferation and migration of CRC cells. In this review, we summarize the data concerning the interaction between TGF-β signaling pathway and miRNAs with the aim to better understanding the CRC molecular mechanisms and hence better management of this disease.
Export Options
About this article
Cite this article as:
Moradi-Marjaneh Reyhaneh , Khazaei Majid , Ferns A. Gordon and Aghaee-Bakhtiari H. Seyed*, The Role of TGF-β Signaling Regulatory MicroRNAs in the Pathogenesis of Colorectal Cancer, Current Pharmaceutical Design 2018; 24 (39) . https://dx.doi.org/10.2174/1381612825666190110150705
DOI https://dx.doi.org/10.2174/1381612825666190110150705 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in Nanomaterials for Diagnosis and Therapy of Leukemia
Recent Patents on Nanomedicine The Therapeutic Impact of Manipulating Microbiota in Inflammatory Bowel Disease
Current Pharmaceutical Design Molecular Surgery with Auger Electron-Emitting Radiopharmaceuticals
Current Radiopharmaceuticals Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Advances in Imaging Gene-Directed Enzyme Prodrug Therapy
Current Pharmaceutical Biotechnology Development of COX-2 Selective Inhibitors - Therapeutic Perspectives
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Intravitreal Injections and Diabetic Macular Edema: Actual and New Therapeutic Options
Current Diabetes Reviews Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia
Current Cancer Drug Targets Nuclear Export as a Novel Therapeutic Target: The CRM1 Connection
Current Cancer Drug Targets In Silico Design of New B-Raf Kinase Type-II Inhibitors Through Combined Molecular Modeling Studies
Letters in Drug Design & Discovery Potential Anticancer Agents. I. Synthesis of Isoxazole Moiety Containing Quinazoline Derivatives and Preliminarily in vitro Anticancer Activity
Anti-Cancer Agents in Medicinal Chemistry Targeting Regulatory T Cells for Anticancer Therapy
Mini-Reviews in Medicinal Chemistry Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Altered Glycosylation of Proteins in Cancer: What Is the Potential for New Anti-Tumour Strategies
Anti-Cancer Agents in Medicinal Chemistry Developing the Evidence Base for Cancer Chemoprevention: Use of Meta-Analysis
Current Drug Targets Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Synthesis, Anticancer Activities, Antimicrobial Activities and Bioavailability of Berberine-Bile Acid Analogues
Letters in Drug Design & Discovery Enhancing the Cytotoxic Activity of Novel Targeted Therapies – Is There a Role for a Combinatorial Approach?
Current Clinical Pharmacology